Skip to content

Arcus Biosciences

US · RCUS #2467 by market cap Listed 2018
15.62 -0.16 -1.01%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:39

Valuation each multiple against its own 5-year range

P/B ratio 7.01 Expensive vs history 95th percentile
5-year average 3.29 · #430 of 514 in Biotechnology
P/E ratio -4.79 In line with history 46th percentile
5-year average 1.59 · forward -5.49
P/S ratio 25.10 Expensive vs history 90th percentile
5-year average 12.58 · forward 114.26 · #227 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Arcus Biosciences (RCUS) 2.25B -4.29 6.28 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value29.64 Economic moatNone UncertaintyVery High

Trading 89.7% below Morningstar's fair value estimate.

Fair value

Arcus Biosciences Inc receives a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 41% discount to our quantitative fair value estimate of $29.64 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics strengthen our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 3.7, which falls in the bottom 40% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

Conversely, the firm's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, ranks in the top 30% compared with global peers. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:39:06 · For reference only, not investment advice and not tailored to your situation.

Arcus Biosciences discussion 0 comments

Add a comment